Kenvue Set for 'Muted' Q4 Amid Difficult Environment, Tylenol Pressure, RBC Says

MT Newswires Live01-24

Kenvue (KVUE) is set to report a "muted" Q4, as the environment remains difficult and the company deals with share pressure in Tylenol and its Skin Health & Beauty brand, RBC Capital Markets analysts said in a Friday note.

The company has not disclosed the release date for its Q4 financial results.

Analysts said that while fundamentals remain difficult, Kenvue will benefit from lapping a soft US cold and flu season a year earlier and temporary market disruptions in the Asia Pacific region.

RBC said that while the flu season picked up later in Q4, it is unlikely to provide a material benefit to the company, as it was late in the quarter.

Regarding litigation surrounding Tylenol's alleged links to autism when used during pregnancy, experts believe that a remand to the lower court is the most likely outcome, analysts said.

RBC has a sector perform rating and a $21 price target on the stock.

Price: 17.72, Change: -0.03, Percent Change: -0.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605404515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-24 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605404515","market":"sh","top_or_hot":-1,"title":"Kenvue Set for 'Muted' Q4 Amid Difficult Environment, Tylenol Pressure, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Kenvue (KVUE) is set to report a \"muted\" Q4, as the environment remains difficult and the company deals with share pressure in Tylenol and its Skin Health &amp; Beauty brand, RBC Capital Markets analysts said in a Friday note.</p><p>The company has not disclosed the release date for its Q4 financial results.</p><p>Analysts said that while fundamentals remain difficult, Kenvue will benefit from lapping a soft US cold and flu season a year earlier and temporary market disruptions in the Asia Pacific region.</p><p>RBC said that while the flu season picked up later in Q4, it is unlikely to provide a material benefit to the company, as it was late in the quarter.</p><p>Regarding litigation surrounding Tylenol's alleged links to autism when used during pregnancy, experts believe that a remand to the lower court is the most likely outcome, analysts said.</p><p>RBC has a sector perform rating and a $21 price target on the stock.</p><p>Price: 17.72, Change: -0.03, Percent Change: -0.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kenvue Set for 'Muted' Q4 Amid Difficult Environment, Tylenol Pressure, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKenvue Set for 'Muted' Q4 Amid Difficult Environment, Tylenol Pressure, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-24 00:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kenvue (KVUE) is set to report a \"muted\" Q4, as the environment remains difficult and the company deals with share pressure in Tylenol and its Skin Health &amp; Beauty brand, RBC Capital Markets analysts said in a Friday note.</p><p>The company has not disclosed the release date for its Q4 financial results.</p><p>Analysts said that while fundamentals remain difficult, Kenvue will benefit from lapping a soft US cold and flu season a year earlier and temporary market disruptions in the Asia Pacific region.</p><p>RBC said that while the flu season picked up later in Q4, it is unlikely to provide a material benefit to the company, as it was late in the quarter.</p><p>Regarding litigation surrounding Tylenol's alleged links to autism when used during pregnancy, experts believe that a remand to the lower court is the most likely outcome, analysts said.</p><p>RBC has a sector perform rating and a $21 price target on the stock.</p><p>Price: 17.72, Change: -0.03, Percent Change: -0.16</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3T34201.USD","symbol_name":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605404515","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605404515","pubTimestamp":1769185621,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kenvue  is set to report a \"muted\" Q4, as the environment remains difficult and the company deals with share pressure in Tylenol and its Skin Health & Beauty brand, RBC Capital Markets analysts said in a Friday note.The company has not disclosed the release date for its Q4 financial results.Analysts said that while fundamentals remain difficult, Kenvue will benefit from lapping a soft US cold and flu season a year earlier and temporary market disruptions in the Asia Pacific region.RBC said that while the flu season picked up later in Q4, it is unlikely to provide a material benefit to the company, as it was late in the quarter.Regarding litigation surrounding Tylenol's alleged links to autism when used during pregnancy, experts believe that a remand to the lower court is the most likely outcome, analysts said.RBC has a sector perform rating and a $21 price target on the stock.Price: 17.72, Change: -0.03, Percent Change: -0.16","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4183":"个人用品","KVUE":"Kenvue Inc","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4588":"碎股","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"加拿大皇家银行表示，在困难的环境和泰诺的压力下，Kenvue第四季度的业绩将“平静”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVUE":1},"content_text":"Kenvue (KVUE) is set to report a \"muted\" Q4, as the environment remains difficult and the company deals with share pressure in Tylenol and its Skin Health & Beauty brand, RBC Capital Markets analysts said in a Friday note.The company has not disclosed the release date for its Q4 financial results.Analysts said that while fundamentals remain difficult, Kenvue will benefit from lapping a soft US cold and flu season a year earlier and temporary market disruptions in the Asia Pacific region.RBC said that while the flu season picked up later in Q4, it is unlikely to provide a material benefit to the company, as it was late in the quarter.Regarding litigation surrounding Tylenol's alleged links to autism when used during pregnancy, experts believe that a remand to the lower court is the most likely outcome, analysts said.RBC has a sector perform rating and a $21 price target on the stock.Price: 17.72, Change: -0.03, Percent Change: -0.16","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605404515","isCrawlerRequest":true}